Genmab Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Genmab Bundle
What is included in the product
Detailed Word Document
Genmab's BCG Matrix analysis spotlights key investment areas for growth and divestment decisions.
Customizable Excel Spreadsheet
One-page Genmab BCG Matrix, providing at-a-glance insights for strategic decisions.
Preview = Final Product
Genmab BCG Matrix
This Genmab BCG Matrix preview is the complete document you’ll receive. It’s a fully functional report, designed for strategic evaluation and is instantly downloadable after purchase.
BCG Matrix Template
Actionable Strategy Starts Here
Explore Genmab's strategic landscape through its BCG Matrix. Discover which products are thriving "Stars," and which are "Cash Cows." Identify the "Dogs" to potentially divest. Uncover the growth potential of "Question Marks." This brief overview is just a glimpse.
Get the full BCG Matrix report for detailed quadrant placements, actionable recommendations, and a clear path to informed investment decisions.
Stars
DARZALEX (daratumumab)
DARZALEX, co-developed with Janssen, saw impressive sales. The drug's 2024 sales reached USD 11.67 billion. This marks its leadership in multiple myeloma treatment. DARZALEX is a key asset for Genmab's royalties.
EPKINLY (epcoritamab)
EPKINLY, a bispecific antibody co-developed with AbbVie, is making waves. It achieved USD 281 million in sales during 2024. Approved in the U.S. and Japan, it targets relapsed lymphoma. Further trials could boost its market presence.
Rinatabart sesutecan (Rina-S)
Rinatabart sesutecan (Rina-S), a Genmab star, came from ProfoundBio acquisition. This ADC is in Phase 3 for ovarian cancer and targets FRα-expressing tumors. It could become a best-in-class treatment, with a large market opportunity. Success could significantly boost Genmab's growth; Genmab's revenue in 2024 was approximately DKK 6.7 billion.
TIVDAK (tisotumab vedotin)
TIVDAK, co-developed with Pfizer, is fully FDA-approved for advanced cervical cancer, demonstrating its proven effectiveness. This approval supports Genmab's revenue through profit-sharing agreements, securing its market presence. Further research into different cancer types could boost its value. TIVDAK's impact on revenue is significant, especially in key markets.
- FDA approval for cervical cancer.
- Partnership with Pfizer.
- Revenue through profit sharing.
- Potential for expansion.
Acasunlimab (GEN1046)
Acasunlimab, a PD-L1x4-1BB bispecific antibody, is progressing to Phase 3 trials for non-small cell lung cancer (NSCLC). Genmab is taking the lead after BioNTech's exit, highlighting its commitment. Successful commercialization could make acasunlimab a major force in the NSCLC market. Positive clinical data are crucial for its potential.
- Phase 3 trials are expected to start in 2024/2025.
- The global NSCLC market was valued at $28.6 billion in 2023.
- Genmab's R&D spending was approximately $550 million in 2024.
- Acasunlimab targets a competitive market with established therapies.
Genmab's Blockbusters: Sales Soar!
Genmab's "Stars" are high-growth products like DARZALEX, generating substantial 2024 sales of USD 11.67B. EPKINLY, with USD 281M in 2024 sales, and Rina-S also show promise.
TIVDAK, fully approved for cervical cancer, and acasunlimab in Phase 3 trials, are set to contribute.
These products drive significant revenue growth for Genmab.
| Product | 2024 Sales (USD) | Key Feature |
|---|---|---|
| DARZALEX | 11.67B | Multiple Myeloma Treatment |
| EPKINLY | 281M | Bispecific Antibody |
| Rina-S | Not Yet Available | ADC for Ovarian Cancer |
| TIVDAK | Significant | Cervical Cancer Treatment |
| Acasunlimab | Potential | Phase 3 Trials (NSCLC) |
Cash Cows
DARZALEX Royalties
Royalties from DARZALEX are a significant revenue source for Genmab. In 2024, these royalties reached DKK 17.352 million, offering financial stability. This steady income stream fuels further investments and growth. Janssen's robust DARZALEX sales ensure a reliable cash flow. This supports Genmab's R&D efforts.
Kesimpta Royalties
Royalties from Kesimpta, an anti-CD20 antibody, are key for Genmab. Kesimpta, sold by Novartis for relapsing multiple sclerosis, provides Genmab with substantial revenue. In 2024, royalties significantly boosted Genmab's financial standing. This steady income supports their pipeline and financial health.
TEPEZZA Royalties
TEPEZZA, developed with Amgen, is approved in Japan for thyroid eye disease, providing Genmab with royalty income. This revenue stream supports Genmab's financial stability, though not as significant as DARZALEX. In 2024, TEPEZZA royalties are a key part of Genmab's portfolio diversification. The royalties help fund ongoing research and development.
RYBREVANT Royalties
RYBREVANT, developed with Johnson & Johnson, generates royalty income for Genmab. This drug, approved for non-small cell lung cancer (NSCLC), provides a steady revenue source. While its contribution might be less than other major products, it still bolsters Genmab's financial standing. In 2024, RYBREVANT's sales are expected to continue growing.
- Royalty income from RYBREVANT supports Genmab's financial health.
- Approved for NSCLC, ensuring a consistent revenue stream.
- Sales continue to grow in 2024.
- It is part of the company's portfolio.
Antibody Technology Platforms
Genmab's antibody technology platforms, like DuoBody and HexaBody, are cash cows. These platforms generate revenue through partnerships and licensing. Collaborations with other companies boost income. Continued development ensures a steady revenue stream. In 2024, Genmab's platform revenues were significant.
- DuoBody technology facilitates the development of bispecific antibodies, which can target two different antigens simultaneously.
- HexaBody technology enhances antibody-dependent cellular cytotoxicity (ADCC), improving the effectiveness of antibody-based therapies.
- Genmab has numerous partnerships with major pharmaceutical companies, licensing its antibody platforms for various drug development programs.
- Royalty income from approved products developed using Genmab's technologies contributes to the cash flow.
Genmab's Revenue Streams: Royalties & Tech Powerhouse
Genmab's cash cows include royalty streams and technology platforms. DARZALEX royalties, at DKK 17.352 million in 2024, offer significant cash flow. Platform revenues from licensing and partnerships also contribute heavily. Steady income supports ongoing R&D.
| Cash Cow | 2024 Revenue (DKK million) | Notes |
|---|---|---|
| DARZALEX Royalties | 17,352 | Steady income, strong sales by Janssen |
| Kesimpta Royalties | Significant | From Novartis for multiple sclerosis |
| Platform Technology | Significant | DuoBody, HexaBody; partnerships |
Dogs
GEN1047 (CD3xB7-H4 bispecific antibody)
GEN1047, a bispecific antibody, aimed at solid tumors, was terminated. This decision aligns with Genmab's strategy to prioritize assets with higher potential. The program, lacking significant revenue, was deemed a cash trap. This move reflects a focus on maximizing returns and resource allocation.
GEN3017 (CD3xCD30 bispecific antibody)
GEN3017, a CD3xCD30 bispecific antibody, was discontinued due to failing to meet Genmab's standards. Early clinical trials in lymphoma showed insufficient promise. The program was seen as having low value. Genmab's 2024 financials reflect strategic portfolio adjustments. The company's focus remains on high-potential assets.
GEN1056 (undisclosed target bispecific antibody)
GEN1056, a bispecific antibody from Genmab and BioNTech, was discontinued because it didn't meet Genmab's standards. The program faced challenges in progress and potential. This termination allowed for resource reallocation to more promising projects. Genmab's focus shifted towards advanced clinical programs in 2024.
Erzotabart (Hexabody-CD38)
Erzotabart, a follow-on to Darzalex, was a program by Genmab that was ultimately discontinued. Johnson & Johnson decided not to proceed with the drug's development. The primary reason was the lack of sufficient differentiation compared to Darzalex, the existing treatment. This strategic decision led Genmab to view Erzotabart as a less promising asset.
- Darzalex's 2024 sales are projected to be around $10 billion.
- Genmab's total revenue in 2023 was approximately $1.8 billion.
- The discontinuation reflects a shift in strategic focus for Genmab.
Early-Stage Programs with Limited Differentiation
Genmab, in 2024, eliminated early-stage programs lacking sufficient differentiation. These programs, not meeting internal benchmarks, were resource-intensive with limited return potential. This strategic shift prioritizes late-stage assets. The company's focus is on high-potential programs for commercial success.
- $57.4 million in research and development expenses in Q1 2024.
- Termination of early-stage programs reflects strategic resource allocation.
- Focus is on assets with higher probability of approval.
Strategic Cuts: Discontinued Programs
Genmab's discontinued programs, like GEN1047 and GEN3017, represent "Dogs" in its portfolio. These assets consumed resources without generating significant revenue. The strategic decisions aimed to eliminate low-potential programs. This redirection supports Genmab's focus on high-value assets for 2024.
| Program | Status | Reason for Discontinuation |
|---|---|---|
| GEN1047 | Discontinued | Lack of potential |
| GEN3017 | Discontinued | Insufficient promise in early trials |
| GEN1056 | Discontinued | Did not meet Genmab's standards |
Question Marks
GEN1055/BNT315 (HexaBody-OX40)
GEN1055/BNT315, Genmab's HexaBody-OX40, is in early trials with BioNTech. This immunotherapeutic agent targets cancer. Its success hinges on trial results. In 2024, Genmab's revenue was approximately DKK 17.9 billion.
GEN1057 (DuoBody-FAPαxDR4)
GEN1057, Genmab's DuoBody-FAPαxDR4, is in early-stage clinical trials. This drug targets FAPα and DR4, showing promise in oncology. Its success hinges on positive trial data. In 2024, Genmab's R&D spending was significant, reflecting its investment in such early-stage assets.
GEN1059/BNT314 (DuoBody-EpCAMx4-1BB)
GEN1059/BNT314, a DuoBody-EpCAMx4-1BB from Genmab and BioNTech, is in early trials. It targets solid tumors, showing early promise. However, it needs to prove its worth in clinical trials to secure its place. Its market potential hinges on demonstrating significant patient benefit. The global oncology market was valued at $192.8 billion in 2023.
GEN1107 (undisclosed target)
GEN1107, targeting an undisclosed area, is in Genmab's early clinical stages. Its potential impact and market feasibility are not yet clear. Further clinical results and strategic choices will impact its standing. The company invested approximately DKK 1.9 billion in R&D in Q3 2023. The success of GEN1107 is crucial for Genmab's future.
- Early-stage clinical trials for GEN1107.
- Uncertainty in the market for undisclosed targets.
- Strategic decisions will shape GEN1107's pipeline role.
- Genmab invested in R&D in 2023.
GEN1160 (undisclosed target)
GEN1160, with an undisclosed target, is in early-stage development, similar to other programs in Genmab's pipeline. It is classified as a Question Mark in the BCG Matrix, indicating high-risk, high-reward potential. This means it needs substantial investment and positive clinical outcomes to increase market share. Early-stage programs like GEN1160 have a significant impact on future growth.
- Early-stage development requires significant financial investment.
- Positive clinical outcomes are crucial for market share growth.
- The Question Mark classification highlights the inherent risks.
- Successful programs contribute substantially to Genmab's portfolio.
GEN1160: High-Risk, High-Reward in Early Trials!
GEN1160, classified as a Question Mark, faces high-risk, high-reward scenarios. These early-stage programs demand substantial investment. Positive outcomes are critical for market share growth. Genmab's Q3 2023 R&D spend was DKK 1.9 billion.
| Program | Stage | Risk | Reward |
|---|---|---|---|
| GEN1160 | Early-stage | High | High |
| R&D Spend (Q3 2023) | Ongoing | Moderate | Significant |
| Market Share | Future | Dependent on Trial | Potentially Large |
BCG Matrix Data Sources
Our BCG Matrix draws on financial reports, market analysis, and industry assessments for dependable insights.
